STRO · Sutro Biopharma, Inc.
Market Cap
$254.36M
Shares
16.58M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$15.34
Open$15.58
Day$14.81–15.58
52W close$7.30–40.91
Avg vol 30d333K
Short int1.8M · 10.9% float · 8.5d
Short vol52%
Last earningsAug 12, 2026
DataJan 2020–Sep 2026
Filing10-Q · Aug 12
Up next
Next earnings call
Nov 11, 2026
Est · unconfirmed
· in 7 wks
filed Aug 12, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$45.70M
Trailing 12 months
Net income (TTM)
−$180.64M
Trailing 12 months
Revenue growth YoY
-84.6%
Year over year
Operating margin
-319.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+94.7%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
10.9%
Latest settlement · 8.5 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 14.8 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
Death cross
Price vs 200-day avg
−32%
below
Price vs 50-day avg
−30%
below
RSI (14)
21
oversold
MACD trend
Negative
52-week position
24%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−28%
trailing
6-month return
−37%
trailing
YTD return
+33%
this year
Relative strength
−57%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
Death cross
50d $22 › 200d $23 — 200d above 50d
Institutional flow
Accumulating
+26% holders QoQ · +40 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
10.91% of float · ▼ -2.5% MoM · 8.5 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
98 holders — mid 3-yr range
Squeeze score
60
elevated · 0–100
Fundamentals
Revenue growth
−26%
Y/Y
EPS growth
+24%
Y/Y
Free cash flow
$-178.8M
Balance sheet
$65.2M
net cash
Quant / Vol
risk profile
Volatility
89%
annualized · 1-yr
Max drawdown
−63%
past year
ATR
8.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
Death cross
Bearish
Price vs 200-day avg
−32%
Bearish
Price vs 50-day avg
−30%
Bearish
RSI (14)
21
Neutral
MACD trend
Negative
Bearish
52-week position
24%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
Death cross
50d $22 › 200d $23 — 200d above 50d
Institutional flow
Accumulating
+26% holders QoQ · +40 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
10.91% of float · ▼ -2.5% MoM · 8.5 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
98 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $7
Now $15 · 24%
Range high $41
vs 200-day avg -32%
vs 50-day avg -30%
50-day below 200-day death cross
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
STRO
this stock
Sutro Biopharma, Inc.
|
$254.36M | +32.6% | -25.7% | — | 10.9% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.84B | +12.1% | +46.2% | 29.6 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.80B | +1.7% | +20.8% | 19.4 | 2.5% |
|
MRNA
Moderna, Inc.
|
$61.50B | +422.3% | +4.3% | — | 9.8% |
|
ARGX
Argenx SE
|
$60.93B | +17.8% | — | — | 2.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| STRO | -9.0% | -27.5% | -37.2% | -24.2% | +32.6% |
| SPY | -0.3% | -0.1% | +20.1% | -0.7% | +11.7% |
| vs SPY | -8.7% | -27.4% | -57.3% | -23.5% | +20.9% |